Resultats de la cerca - Isabelle Ravelingien
- Mostrar 1 - 6 resultats de 6
-
1
Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial per Frédéric Houssiau, David D’Cruz, Shirish Sangle, Philippe Rémy, Carlos Vasconcelos, Radmila Petrović, Christoph Fiehn, Enrique de Ramón Garrido, Inge-Magrethe Gilboe, Maria G. Tektonidou, Daniël Blockmans, Isabelle Ravelingien, Véronique Le Guern, Geneviève Depresseux, Loı̈c Guillevin, Ricard Cervera
Publicat 2010Artigo -
2
Long-term follow-up of the <i>MAINTAIN</i> Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis per Farah Tamirou, David D’Cruz, Shirish Sangle, Philippe Rémy, Carlos Vasconcelos, Christoph Fiehn, María del Mar Ayala Gutiérrez, Inge-Magrethe Gilboe, Maria G. Tektonidou, Daniël Blockmans, Isabelle Ravelingien, Véronique Le Guern, Geneviève Depresseux, Loı̈c Guillevin, Ricard Cervera, Frédéric Houssiau
Publicat 2015Artigo -
3
Repeat kidney biopsies fail to detect differences between azathioprine and mycophenolate mofetil maintenance therapy for lupus nephritis: data from the MAINTAIN Nephritis Trial per Maria Stoenoiu, Selda Aydın, Maria G. Tektonidou, Isabelle Ravelingien, Véronique Le Guern, Christoph Fiehn, Philippe Rémy, Michel Delahousse, P Petera, T. Quemeneur, Carlos Vasconcelos, David D’Cruz, I-M Gilboe, Michel Jadoul, A. Karras, G Depresseux, Loı̈c Guillevin, Ricard Cervera, J.-P. Cosyns, Frédéric Houssiau
Publicat 2011Artigo -
4
Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the random... per Patrick Verschueren, Diederik De Cock, Luk Corluy, Rik Joos, C. Langenaken, V. Taelman, F. Raeman, Isabelle Ravelingien, K. Vandevyvere, Jan Lenaerts, Elke Geens, Piet Geusens, J. Vanhoof, Anne Durnez, J Remans, Bert Vander Cruyssen, E. Van Essche, A. Sileghem, G. De Brabanter, Johan Joly, Kristien Van der Elst, Sabrina Meyfroidt, René Westhovens
Publicat 2015Artigo -
5
Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid a... per Patrick Verschueren, Diederik De Cock, Luk Corluy, Rik Joos, C. Langenaken, V. Taelman, F. Raeman, Isabelle Ravelingien, K. Vandevyvere, Jan Lenaerts, Elke Geens, Piet Geusens, J. Vanhoof, Anne Durnez, J Remans, Bert Vander Cruyssen, E. Van Essche, A. Sileghem, G. De Brabanter, Johan Joly, Sabrina Meyfroidt, Kristien Van der Elst, René Westhovens
Publicat 2014Artigo -
6
Effectiveness of different combinations of DMARDs and glucocorticoid bridging in early rheumatoid arthritis: two-year results of CareRA per Veerle Stouten, René Westhovens, Sofia Pazmino, Diederik De Cock, Kristien Van der Elst, Johan Joly, Patrick Verschueren, B. Maeyaert, G. De Brabanter, Mieke Devinck, C. Langenaken, J. Lenaerts, L Corluy, J Remans, Bert Vander Cruyssen, Isabelle Ravelingien, E. Van Essche, K. Vandevyvere, Anne Durnez, August Verbruggen, Elke Geens, F. Raeman, Rik Joos, Kurt de Vlam, V. Taelman, J. Vanhoof, Michiel Coppens, Piet Geusens, A. Sileghem, Paul G.A. Volders, Filip Van den Bosch, Patrick Verschueren, R Westhovens
Publicat 2019Artigo
Eines de cerca:
Matèries relacionades
Internal medicine
Medicine
Disease
Azathioprine
Gastroenterology
Lupus nephritis
Mycophenolate
Mycophenolic acid
Nephritis
Rheumatoid arthritis
Transplantation
Adverse effect
Chemotherapy
Computer science
Immunology
Methotrexate
Prednisone
Randomized controlled trial
Rheumatology
Surgery
Biopsy
Bridging (networking)
C-reactive protein
Clinical endpoint
Cobra
Cohort
Computer network
Coronavirus disease 2019 (COVID-19)
Cyclophosphamide
Glucocorticoid